Macropinocytosis requires Gal-3 in a subset of patient-derived glioblastoma stem cells

Macropinocytosis requires Gal-3 in a subset of patient-derived glioblastoma stem cells

Seguin et al demonstrated in glioblastoma patient-derived stem cells that a subset of glioblastoma tumours is dependent on macropinocytosis mediated survival through a Galectin-3/RAB10/beta 1 integrin axis. They used both genetic and pharmacologic inhibition of Galectin-3 in vivo and in vitro to ide...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Laetitia Seguin, Soline Odouard, Francesca Corlazzoli, Sarah Al Haddad, Laurine Moindrot, Marta Calvo Tardón, Mayra Yebra, Alexey Koval, Eliana Marinari, Viviane Bes, Alexandre Guérin, Mathilde Allard, Sten Ilmjärv, Vladimir L. Katanaev, Paul R. Walker, Karl-Heinz Krause, Valérie Dutoit, Jann N. Sarkaria, Pierre-Yves Dietrich, Érika Cosset
Format: article
Langue:EN
Publié: Nature Portfolio 2021
Sujets:
Biology (General)
QH301-705.5
Accès en ligne:https://doaj.org/article/af6a9382a80a4f38a4b6f252cbc7ee7f
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
Description
Résumé:Seguin et al demonstrated in glioblastoma patient-derived stem cells that a subset of glioblastoma tumours is dependent on macropinocytosis mediated survival through a Galectin-3/RAB10/beta 1 integrin axis. They used both genetic and pharmacologic inhibition of Galectin-3 in vivo and in vitro to identify underlying mechanisms and define a Galectin-3/macropinocytosis molecular signature, which could inform the development of anti-tumour therapeutic strategies.

Documents similaires